Anticancer Nanomedicine: Recent Advances
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".
Deadline for manuscript submissions: closed (31 March 2021) | Viewed by 2890
Special Issue Editor
Interests: nanomedicine; cancer; personalized Medicine
Special Issue Information
Dear Colleagues,
Cancer continues to be one of the main causes of death worldwide. A concerted effort in research is urgently needed to decrease the health and socioeconomic impact of cancer. Nowadays, it is known that nanomedicine can contribute to the development of advanced and more efficient therapeutics, helping to fight cancer by providing improved outcomes in terms of toxicity and overall survival. Recent advances regarding the role of the tumor microenvironment and the immune system in cancer progression and formation of metastasis have prompted the development of new nanomedicines specifically designed to target cell populations other than cancer cells, as well as the development of combinatory treatments to provide a holistic approach. In parallel, nanomedicine can contribute to the development of innovative diagnosis modalities for the early detection of cancer and follow-up, as well as more advanced nanotheranostics. This Special Issue aims to incorporate a summary of up-to-date articles to provide a comprehensive overview of the most recent advances in cancer nanomedicine.
Dr. Maria De La Fuente
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer
- metastasis
- tumor microenvironment
- personalized medicine
- nanomedicine
- nanotheranostics
- diagnostics
- immunotherapies
- advanced therapies
- combinatory therapies
